This blog features with:
- The key points of maintaining consistency in causality assessment
- Key considerations before and during causality evaluation
- A structured approach to applying causality principles in real case processing
Introduction
Causality assessment is one of the most critical and intellectually demanding components of pharmacovigilance. Determining whether an adverse event (AE) is related to a medicinal product requires structured clinical reasoning, scientific judgment, and careful evaluation of available evidence.
Before assigning a causality category, the assessor must ensure that the case information is accurate, complete, and consistently coded. In this write-up, we explore the nuanced aspects of causality assessment in detail. Let us now examine these principles systematically.
“Causality assessment is not about proving certainty—it is about weighing evidence with scientific discipline and clinical judgment.”
Key Points Before and During Causality Assessment
When assessing causality in an adverse event (AE) report, a systematic and structured approach is essential. The following points should be carefully considered:
1. Data Quality and Case Integrity
- Ensure that coding (e.g., MedDRA terms) is accurate and consistent.
- Confirm that the case information is as complete as possible before evaluation.
- Verify that clinical details are clear and internally consistent.
2. Clarity of the Case
- Determine whether the case is straightforward and clearly interpretable.
- Some cases may be self-evident, while others require deeper clinical analysis.
3. Objective vs. Subjective Evidence
- Give greater weight to objective findings (laboratory values, imaging, biopsy results).
- Recognize that subjective symptoms require careful contextual evaluation.
4. Define the Type of Causality Being Assessed
Be clear about the perspective of assessment:
- Regulatory causality – Based on reporting standards and signal detection requirements. (No grey zone)
- Medical causality – Attempts to judge & quantify likelihood of causal association for use in signaling & labeling
- Legal causality – Based on proof standards applicable in legal proceedings.
5. Apply the Fundamental Criteria for Causality
Evaluate the case against established principles:
- Pharmacological basis and prior knowledge of known adverse drug reactions (ADRs)
- Temporal association between drug exposure and adverse event onset
- Biological plausibility of the reaction
- Alternative explanations, including underlying disease or comorbidities
- Comprehensive review of all reported data, including identification of missing or incomplete information
6. Dechallenge and Rechallenge Information
- Assess whether the event improved upon discontinuation (dechallenge).
- Evaluate whether recurrence occurred after re-administration (rechallenge), if applicable.
7. Frequency of Occurrence
- Consider the number of similar cases reported in clinical trials or post-marketing data.
8. Pharmacokinetic Considerations
- Assess whether drug interactions or metabolic factors could explain the event.
9. Consistency in Time to Onset
- Compare time-to-onset patterns across similar reported cases.
10. Known Safety Profile
- Determine whether similar adverse events are already documented for the product.
11. Class Effect
- Evaluate whether drugs with similar pharmacological properties are associated with the same adverse event.
12. Dose and Duration of Exposure
- Confirm whether the amount and duration of drug exposure are sufficient to reasonably cause the event.
13. Background Incidence
- Assess whether the event has a low baseline occurrence in the general population, strengthening the likelihood of association.
14. Concomitant Medications
- Evaluate whether co-medications are unlikely contributors to the adverse event.
15. Credibility of the Reporter
- Consider the professional background and reliability of the reporter (e.g., healthcare professional vs. consumer), while avoiding bias.
How do you approach causality assessment in your project?
Comment below and join the discussion. Your insights could help fellow safety professionals learn and grow.
Conclusion
Causality assessment remains one of the most complex and essential responsibilities in pharmacovigilance. It demands more than a checklist approach; it requires structured reasoning, clinical judgment, and careful integration of scientific evidence. No single criterion determines causality. Instead, conclusions emerge from the collective evaluation of temporal relationships, biological plausibility, alternative explanations, dechallenge and rechallenge information, pharmacological knowledge, and supporting safety data.
Ultimately, causality assessment is both a science and an art—grounded in evidence, guided by methodology, and refined through experience. A systematic and disciplined approach ensures that each case contributes meaningfully to the broader framework of drug safety monitoring.
Do you find this content relevant and helpful for learning and applying causality assessment in real case processing as a beginner? If you feel anything important is missing, please share your thoughts in the comments below.
